EINDHOVEN, The Netherlands and ZURICH, November 15, 2017 /PRNewswire/ — Xeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed EUR45 million ($52 million) Series C financing. The funding round was led by a global strategic investor with participation […]



